

In the claims:

Please amend the claims as follows:

1 - 15 (Cancelled)

16. (Currently and previously amended) A method for treating or ~~preventing~~ pretreating Japanese cedar pollen allergy in a subject in need thereof, the method comprising:

- (a) identifying an HLA class II molecule expressed by the subject;
- (b) selecting an antigenic peptide derived from Japanese cedar pollen allergen Cry j 1 or Cry j 2, wherein the antigenic peptide binds to HLA class II molecule and wherein:
  - (1) when the HLA class II molecule identified in step (a) is DQA1\*0102-DQB1\*0602, the antigenic peptide is selected from the group consisting of SEQ ID NO: 1, 5, 7, 9, 10, 21, 23, and 142;
  - (2) when the HLA class II molecule identified in step (a) is DPA1\*0101-DPB1\*0501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 2, 8, and 15;
  - (3) when the HLA class II molecule identified in step (a) is DPA1\*0101-DPB1\*0201, the antigenic peptide is SEQ ID NO: 17;
  - (4) when the HLA class II molecule identified in step (a) is DPA1\*0202-DPB1\*0501, the antigenic peptide is SEQ ID NO: 22;
  - (5) when the HLA class II molecule identified in step (a) is DRB5\*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 3, 4, 14, and 19;
  - (6) when the HLA class II molecule identified in step (a) is DRB1\*0901, the antigenic peptide is selected from the group consisting of SEQ ID NO: 6, 7, 12, 16, and 20;
  - (7) when the HLA class II molecule identified in step (a) is DRB4\*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 7, 12, and 18; and

- (8) when the HLA class II molecule identified in step (a) is DRB1\*1501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 13 and 19; and
- (c) administering the selected antigenic peptide to the subject.

17. (Previously amended) A customized pharmaceutical composition for treating a subject suffering from a Japanese cedar pollen allergy, the composition comprising:

(a) an effective amount of an antigenic peptide derived from Japanese cedar pollen allergen Cry j 1 or Cry j 2, wherein the antigenic peptide binds to an HLA class II molecule expressed by the subject and wherein:

- (1) when the subject expresses the HLA class II molecule DQA1\*0102-DQB1\*0602, the antigenic peptide is selected from the group consisting of SEQ ID NO: 1, 5, 7, 9, 10, 21, 23, and 142;
- (2) when the subject expresses the HLA class II molecule DPA1\*0101-DPB1\*0501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 2, 8, and 15;
- (3) when the subject expresses the HLA class II molecule DPA1\*0101-DPB1\*0201, the antigenic peptide is SEQ ID NO: 17;
- (4) when the subject expresses the HLA class II molecule DPA1\*0202-DPB1\*0501, the antigenic peptide is SEQ ID NO: 22;
- (5) when the subject expresses the HLA class II molecule DRB5\*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 3, 4, 14, and 19;
- (6) when subject expresses the HLA class II molecule DRB1\*0901, the antigenic peptide is selected from the group consisting of SEQ ID NO: 6, 7, 12, 16, and 20;
- (7) when the subject expresses the HLA class II molecule DRB4\*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 7, 12, and 18; and

Applicant : Toshio Sone et al.  
Serial No. : 09/308,027  
Filed : August 16, 1999  
Page : 6 of 10

Attorney's Docket No.: 14883-031001/ M1-808PCT-US

- (8) when the subject expresses the HLA class II molecule DRB1\*1501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 13 and 19; and
- (b) a pharmaceutically acceptable diluent or carrier.